COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Mult Scler Relat Disord. 2021 Apr:49:102775. doi: 10.1016/j.msard.2021.102775. Epub 2021 Jan 19.
No abstract available

Keywords: COVID-19; Cladribine; Multiple sclerosis; SARS-CoV-2; Vaccination; vaccine.

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19*
  • Cladribine / therapeutic use
  • Humans
  • Multiple Sclerosis* / drug therapy
  • Risk Factors
  • SARS-CoV-2
  • Vaccination

Substances

  • Cladribine